Clinical Trial Update: Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing olanzapine to prevent vomiting in children and adolescents undergoing highly emetogenic chemotherapy; study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: Shanghai Children's Medical Center | Conditions: Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer | Phase 3 | Status: NOT_YET_RECRUITING